Author:
Sadou Yayé Hassane,Secrétan Philippe-Henri,Henriet Théo,Bernard Mélisande,Amrani Fatma,Akrout Wiem,Tilleul Patrick,Yagoubi Najet,Do Bernard
Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference13 articles.
1. S. James, A. Akerblom, C.P. Cannon, S. Husted, H. Katus, A. Skene, P.G. Steg, R.F. Storey, R. Harrington, R. Becker, L. Wallentin. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am. Heart J. 157 (2009) 599–605.
2. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy;Storey;J. Am. Coll. Cardiol.,2010
3. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention;Alexopoulos;J. Am. Coll. Cardiol.,2012
4. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
5. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline)
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献